Liquid Biopsy MarketSize, Share & Industry Analysis, 2026-2034By BiomarkerBy TechnologyBy ApplicationBy End UserBy Sample Type
Full title & scope — all 5 axes with their segments
Liquid Biopsy Market Size, Share & Industry Analysis, By Biomarker (Circulating Nucleic Acids, CTC, Exosomes/Microvesicles, Circulating Proteins), By Technology (Multi-gene-parallel Analysis, Single Gene Analysis), By Application (Diagnosis & Companion Diagnostics, Treatment Selection & Monitoring, Recurrence/MRD Monitoring, Early Cancer Screening), By End User (Reference/Central Laboratories, Hospitals & Diagnostic Laboratories, Pharmaceutical & Biotechnology Companies, Academic & Research Institutes), By Sample Type (Blood-based, Urine-based, Other Biofluids), and Regional Forecast, 2026-2034
How the estimates were built: data sources, modelling approach and validation steps.
- 01By BiomarkerCirculating Nucleic Acids · CTC · Exosomes/Microvesicles
- 02By TechnologyMulti-gene-parallel Analysis · Single Gene Analysis
- 03By ApplicationDiagnosis & Companion Diagnostics · Treatment Selection & Monitoring · Recurrence/MRD Monitoring
- 04By End UserReference/Central Laboratories · Hospitals & Diagnostic Laboratories · Pharmaceutical & Biotechnology Companies
- 05By Sample TypeBlood-based · Urine-based · Other Biofluids
- 06By Region
Market Analysis & Outlook
Liquid biopsy testing analyzes circulating tumor material such as cell-free nucleic acids, whole tumor cells, exosomes, or tumor-derived proteins drawn from blood or another body fluid, rather than from a surgical tissue sample. Oncologists order these tests to select or adjust cancer treatment, to check for early disease recurrence, and increasingly to screen for cancer before symptoms appear. Buyers span hospital and reference laboratories that run the assays, pharmaceutical companies that use them to select clinical trial patients, and the diagnostic manufacturers and specialty labs that develop and sell the underlying tests.
Growth of 14.89% a year carries the global liquid biopsy market from USD 7.25 billion in 2025 to USD 26.25 billion in 2034. The full series behind that rate covers USD 2.7 billion in 2020, USD 5.85 billion in 2024, USD 8.65 billion in 2026 and USD 15.85 billion in 2030, with 2025 as the base year.
The biomarker mix shifts over the period. Circulating Nucleic Acids is the largest line in 2025 at USD 4.21 billion, a 58.07% share, moving to USD 16.28 billion and 62.02% by 2034. Exosomes/Microvesicles grows fastest at 17.7%, taking its share from 12% to 15.01%, while CTC grows slowest at 10.8%. The lines gaining share are Circulating Nucleic Acids and Exosomes/Microvesicles. CTC and Circulating Proteins lose share without losing revenue.
Cut by technology, the largest line is Multi-gene-parallel Analysis (NGS): 68% of 2025 revenue, worth USD 4.93 billion, and 74.02% at USD 19.43 billion by 2034. It is also the fastest-growing line on this axis at 16.47%, so the split concentrates over the period instead of balancing. Both this axis and the biomarker one divide the same revenue, which is why they are alternative views, not components.
Geographically, 42.07% of 2025 revenue sits in North America (USD 3.05 billion rising to USD 9.98 billion) ahead of Europe at 27.03% and USD 1.96 billion. Middle East and Africa is smallest, at 3.86%. Share shifts toward Asia Pacific, Latin America and Middle East and Africa over the forecast period, so the regional split repays a close reading.
Behind these figures sit five regions, four biomarker lines and five segmentation axes, each reported for every year from 2020 to 2034. The headline 2025 value is arrived at by triangulating published aggregates against category proxies, not by an independent count, and the same applies to the segment, regional and country breakdowns drawn from it.
Market Size, 2020–2034
USD BillionRevenue in USD Billion. Values up to 2025 are actuals; 2026–2034 are forecast.
Key Takeaways
- A forecast-period rate of 14.89% takes the market from USD 7.25 billion in 2025 to USD 26.25 billion in 2034, against 21.84% recorded over the 2020-2025 historical period.
- The largest line by biomarker is Circulating Nucleic Acids, worth USD 4.21 billion and 58.07% of revenue in 2025, rising to USD 16.28 billion and 62.02% by 2034.
- At 17.7%, Exosomes/Microvesicles grows faster than any other biomarker line, moving from USD 0.87 billion and 12% of revenue in 2025 to USD 3.94 billion and 15.01% in 2034.
- Scenario range for 2034 runs from USD 22.31 billion in the bear case to USD 30.19 billion in the bull case, against a base-case USD 26.25 billion, the spread a plan built on this forecast has to absorb.
- 42.07% of 2025 revenue is generated in North America, worth USD 3.05 billion and rising to USD 9.98 billion by 2034; Middle East and Africa is smallest at 3.86%.
- 90.16% of North America's base-year revenue comes from the United States alone: USD 2.75 billion in 2025, rising to USD 8.98 billion by 2034, which is why it is that region's worked example.
- The study covers 2020 through 2034 with 2025 as the base year, reporting five regions and five segmentation axes separately, with revenue, share and a growth rate for every line in each year.
Market Trends
Revenue Share, By by biomarker
Base year 2025Circulating Nucleic Acids leads with 58.1% of by biomarker segment revenue.
Share of by biomarker segment revenue, most recent base year.
Read across the forecast period, the global liquid biopsy market shows movement in three places: biomarker composition, regional weight, and the 14.89% rate applied to the whole.
None of them reverses the market's direction. Every line and every region grows in absolute terms across the period; the movement is in which of them captures the revenue added.
Exosomes/Microvesicles grows faster than CTC. Between 2026 and 2034, 17.7% growth in Exosomes/Microvesicles against 10.8% in CTC pulls the biomarker mix apart. Over the forecast period that moves Exosomes/Microvesicles from 12% of revenue to 15.01%, and CTC from 22.07% to 16%. Neither contracts: USD 0.87 billion becomes USD 3.94 billion, USD 1.6 billion becomes USD 4.2 billion. What the spread decides is which of them a supplier's revenue is exposed to.
Regional weight shifts toward Asia Pacific, Latin America and Middle East and Africa. Asia Pacific moves from 22.07% of revenue in 2025 to 27.01% in 2034, worth USD 1.6 billion rising to USD 7.09 billion; Latin America moves from 4.97% of revenue in 2025 to 5.49% in 2034, worth USD 0.36 billion rising to USD 1.44 billion; Middle East and Africa moves from 3.86% of revenue in 2025 to 4.5% in 2034, worth USD 0.28 billion rising to USD 1.18 billion. Against that, North America at 42.07% moving to 38.02%, Europe at 27.03% moving to 25%, a fall in share, not in revenue. Growth is therefore not something a participant inherits from the market; it depends on which regions its revenue is weighted toward.
Growth compounds at 14.89% without a step change. The market moves through USD 2.7 billion in 2020, USD 5.85 billion in 2024, USD 7.25 billion in 2025, USD 8.65 billion in 2026, USD 15.85 billion in 2030 and USD 26.25 billion in 2034. No year breaks the trajectory, and the 14.89% forecast rate compares with 21.84% recorded over 2020-2025, a continuation, not an inflection. A plan built on this market is therefore a plan about capturing a share of steady expansion, which is decided on the biomarker and regional axes, not by the headline rate.
Market Growth Factors
Exosomes/Microvesicles adds the most incremental growth
Market Drivers
3- 01Exosomes/Microvesicles adds the most incremental growth
17.7% growth in Exosomes/Microvesicles, against 14.89% for the market as a whole, moves it from USD 0.87 billion and 12% of revenue in 2025 to USD 3.94 billion and 15.01% in 2034. The market's overall 14.89% depends on that rate holding: at the 10.8% recorded by CTC, the same revenue base would compound to a materially smaller 2034 total. Where a supplier sits on this axis therefore decides whether it grows with the market or below it.
- 02Regional weight, not regional count
The largest regional base is North America: USD 3.05 billion in 2025 at 42.07% of the global total, USD 9.98 billion by 2034, still 38.02%. Europe is next at 27.03% of revenue, USD 1.96 billion in 2025 and USD 6.56 billion in 2034. Because both the existing revenue and the revenue added concentrate in these two, regional weighting matters more to a forecast than regional count does.
- 03The base has grown every year since 2020
Revenue rose through USD 2.7 billion in 2020, USD 5.85 billion in 2024 and USD 7.25 billion in 2025, a compound 21.84% across the historical period. The forecast period then runs at 14.89%, ending 2034 at USD 26.25 billion. Because the growth is already in the record and not only in the projection, the rate is held flat across the forecast instead of ramped, and the risk in the number sits in the mix assumptions, not in whether the market grows at all.
Growth drivers
| # | Growth driver | Impact | Gross contribution (Billion) | 2026-28 | 2029-31 | 2032-34 |
|---|---|---|---|---|---|---|
| 1 | Expansion of companion-diagnostic approvals built on ctDNA assays | High | +6.2 | High | High | Medium |
| 2 | Growth in molecular residual disease monitoring adoption | High | +4.8 | Medium | High | High |
| 3 | Scaling of multi-cancer early detection screening pilots | Medium-High | +3.4 | Low | Medium | High |
| 4 | Broader clinical-trial use for patient stratification | Medium-High | +2.6 | Medium | Medium | Medium |
| 5 | Falling multi-gene panel costs widening addressable volume | Medium | +2.1 | Medium | Medium | High |
| 6 | Others | Low | +1.2 | Low | Low | Low |
| Total | +20.3 | |||||
Restraints
| # | Restraint | Impact | Estimated reduction (Billion) | 2026-28 | 2029-31 | 2032-34 |
|---|---|---|---|---|---|---|
| 1 | Inconsistent payer coverage outside the United States | Medium-High | −0.85 | High | Medium | Low |
| 2 | Pre-analytical sample variability limiting assay reliability | Medium | −0.45 | Medium | Medium | Low |
| Total | −1.3 | |||||
Drivers contribute 20.3 Billion and restraints remove 1.3 Billion, a net 19 Billion, which is the revenue the market adds between the base year and 2034. Contributions are CDI estimates, apportioned so that they reconcile with the forecast rather than being read from it.
Separate the 14.89% into its parts and three show up: an already-large base compounding, the biomarker mix moving toward its faster lines, and regional growth landing unevenly.
Restraining Factors
Downside case: USD 22.31 billion by 2034, against USD 26.25 billion in the base case
Market Restraints
2- 01Downside case: USD 22.31 billion by 2034, against USD 26.25 billion in the base case
The study's downside path assumes the bear case assumes reimbursement for screening and recurrence-monitoring indications stalls near its current scope, and panel pricing declines more slowly than the base case assumes, and ends 2034 at USD 22.31 billion against the USD 26.25 billion base case, the same USD 7.25 billion base year, a slower forecast period.
- 02The largest line is not the fastest
With 22.07% of 2025 revenue (USD 1.6 billion) CTC is where most of the market sits, and it grows at only 10.8% against the market's 14.89%. Revenue still reaches USD 4.2 billion by 2034 and share still falls to 16%: a drag on the average, not a decline.
Market Opportunities
What the bull case turns on
Market Opportunities
2- 01What the bull case turns on
The upside path assumes the bull case assumes companion-diagnostic and MRD reimbursement broadens faster than its recent pace, and at least one multi-cancer screening test gains and holds broad payer coverage. It ends 2034 at USD 30.19 billion against a USD 26.25 billion base case, off the same USD 7.25 billion base year.
- 02The opening is on the biomarker axis, not the regional one
Exosomes/Microvesicles grows at 17.7% against 14.89% for the market, adding revenue from USD 0.87 billion in 2025 to USD 3.94 billion in 2034 and taking its share from 12% to 15.01%. It is the place on this axis where share changes hands at scale, so it is where an entrant can take position without displacing the incumbent in Circulating Nucleic Acids.
Market Challenges
Revenue is concentrated in Circulating Nucleic Acids
Market Challenges
2- 01Revenue is concentrated in Circulating Nucleic Acids
With 58.07% of 2025 revenue and 62.02% of 2034 revenue (USD 4.21 billion rising to USD 16.28 billion) Circulating Nucleic Acids is where the market's exposure sits. Anything that changes demand for it changes the headline number; nothing else on the axis carries that weight.
- 02North America is largely the United States
The United States generates USD 2.75 billion of North America's USD 3.05 billion in 2025, 90.16% of the region, reaching USD 8.98 billion by 2034. The consequence is that regional risk here is really country risk wearing a larger label.
Segmentation Analysis
5 axesSegmentation runs along five axes: biomarker, technology, application, end user and sample type. Revenue does not add across them: each is a different cut of the same total.
All four biomarker lines expand in revenue terms over the forecast period. Share is the dividing line; two take it, the others cede it.
By Biomarker · 4 segments
Circulating Nucleic Acids Held the Dominant Share of the Biomarker Segment in 2025
- Largest Circulating Nucleic Acids · 58.1%
- Fastest Exosomes/Microvesicles · 17.7%
- Moves most CTC · -6.1 pts
- Order by 2034 unchanged
| Segment | 2025 | Share | 2034 | Share | CAGR |
|---|---|---|---|---|---|
| Circulating Nucleic Acids | $4.21B | 58.1% | $16.28B | 62%+4 | 15.7% |
| CTC | $1.60B | 22.1% | $4.20B | 16%-6.1 | 10.8% |
| Exosomes/Microvesicles | $0.87B | 12% | $3.94B | 15%+3 | 17.7% |
| Circulating Proteins | $0.57B | 7.9% | $1.83B | 7%-0.9 | 13.4% |
Circulating nucleic acid assays lead because ctDNA and ctRNA testing underpins most approved companion-diagnostic and residual-disease monitoring assays, concentrating laboratory and pharmaceutical demand there. Exosome and microvesicle testing grows fastest as new extraction and profiling methods move exosomal RNA and protein content from research into early clinical use, a transition that produces a steeper adoption curve than in the already-established categories. The order does not change: Circulating Nucleic Acids is still largest in 2034, and what moves is how much it holds. This is the axis the estimation prices in full, year by year, and the one the regional chapters cut against.
By Technology · 2 segments
Multi-gene-parallel Analysis (NGS) Both Leads the Technology Axis and Grows Fastest on It
- Largest Multi-gene-parallel Analysis (NGS) · 68%
- Fastest Multi-gene-parallel Analysis (NGS) · 16.5%
- Moves most Multi-gene-parallel Analysis (NGS) · +6 pts
- Order by 2034 unchanged
| Segment | 2025 | Share | 2034 | Share | CAGR |
|---|---|---|---|---|---|
| Multi-gene-parallel Analysis (NGS) | $4.93B | 68% | $19.43B | 74%+6 | 16.5% |
| Single Gene Analysis (PCR Microarrays) | $2.32B | 32% | $6.82B | 26%-6 | 12.7% |
Multi-gene parallel analysis leads because a single next-generation-sequencing panel can answer several companion-diagnostic questions from one blood draw, and oncologists and payers increasingly expect exactly that. It grows fastest of the two as sequencing costs fall and regulatory clearances extend its use beyond late-stage cancer into earlier monitoring, widening the pool of patients it can serve. Multi-gene-parallel Analysis (NGS) remains the largest line through 2034, so the axis changes in proportion, not in order.
By Application · 4 segments
Scale in Diagnosis & Companion Diagnostics and Growth in Early Cancer Screening Define the Application Axis
- Largest Diagnosis & Companion Diagnostics · 40%
- Fastest Early Cancer Screening · 19.9%
- Moves most Diagnosis & Companion Diagnostics · -6 pts
- Order by 2034 unchanged
| Segment | 2025 | Share | 2034 | Share | CAGR |
|---|---|---|---|---|---|
| Diagnosis & Companion Diagnostics | $2.90B | 40% | $8.93B | 34%-6 | 13.3% |
| Treatment Selection & Monitoring | $1.96B | 27% | $6.56B | 25%-2 | 14.4% |
| Recurrence/MRD Monitoring | $1.52B | 21% | $6.30B | 24%+3 | 17.1% |
| Early Cancer Screening | $0.87B | 12% | $4.46B | 17%+5 | 19.9% |
Diagnosis and companion-diagnostic testing leads because it is the most reimbursed and clinically established use of liquid biopsy, tied directly to treatment selection at initial diagnosis. Early cancer screening grows fastest as multi-cancer detection assays move from pilot programs into broader at-risk population testing, expanding off a far smaller base than the other three uses. The order does not change: Diagnosis & Companion Diagnostics is still largest in 2034, and what moves is how much it holds.
By End User · 4 segments
Reference/Central Laboratories Led by End user in 2025, with Pharmaceutical & Biotechnology Companies Growing Fastest
- Largest Reference/Central Laboratories · 38.1%
- Fastest Pharmaceutical & Biotechnology Companies · 17.2%
- Moves most Pharmaceutical & Biotechnology Companies · +3 pts
- Order by 2034 unchanged
| Segment | 2025 | Share | 2034 | Share | CAGR |
|---|---|---|---|---|---|
| Reference/Central Laboratories | $2.76B | 38.1% | $9.45B | 36%-2.1 | 14.7% |
| Hospitals & Diagnostic Laboratories | $2.18B | 30.1% | $8.14B | 31%+0.9 | 15.8% |
| Pharmaceutical & Biotechnology Companies | $1.45B | 20% | $6.04B | 23%+3 | 17.2% |
| Academic & Research Institutes | $0.86B | 11.9% | $2.62B | 10%-1.9 | 13.2% |
Reference and central laboratories lead because most oncology liquid biopsy volume routes through a small number of high-throughput labs rather than being tested inside individual hospitals. Pharmaceutical and biotechnology company use grows fastest as more clinical trials add ctDNA-based patient selection and monitoring endpoints, a use case still expanding off a smaller base than routine clinical testing. Reference/Central Laboratories remains the largest line through 2034, so the axis changes in proportion, not in order.
By Sample Type · 3 segments
Blood-based (Plasma/Serum) Held the Dominant Share of the Sample type Segment in 2025
- Largest Blood-based (Plasma/Serum) · 88%
- Fastest Urine-based · 18.6%
- Moves most Blood-based (Plasma/Serum) · -3 pts
- Order by 2034 unchanged
| Segment | 2025 | Share | 2034 | Share | CAGR |
|---|---|---|---|---|---|
| Blood-based (Plasma/Serum) | $6.38B | 88% | $22.31B | 85%-3 | 14.9% |
| Urine-based | $0.51B | 7% | $2.36B | 9%+2 | 18.6% |
| Other Biofluids (CSF, Pleural Fluid, Saliva) | $0.36B | 5% | $1.58B | 6%+1 | 17.9% |
Blood-based sampling leads because plasma and serum draws are the least invasive option that still yields enough circulating material for routine oncology testing, and most approved assays are validated on blood alone. Urine-based testing grows fastest as assays validated for bladder and other urologic cancers move from research into early commercial use, expanding off a smaller base than blood-based testing. The order does not change: Blood-based (Plasma/Serum) is still largest in 2034, and what moves is how much it holds.
Regional Insights
Regional Revenue Share
Base year 2025Share of global revenue in the base year.
Only the leading region's share is published outside the report; pins mark the region, not a specific country.
North America Market Analysis
The largest region covered — 4.1 points of share move elsewhere by 2034, while revenue still grows 3.3×.
- Rank 1 of 5
- 2025 share 42.1%
- By 2034 38%
- Revenue $3.05B → $9.98B
42.07% of the global liquid biopsy market sits in North America in 2025, worth USD 3.05 billion with USD 9.98 billion projected for 2034. Among the five regions it ranks first by revenue in both years.
Share settles at 38.02% in 2034, a shift in share, not in direction: revenue climbs every year while the market's centre of gravity moves elsewhere.
The biomarker mix reported at global level applies here, with Circulating Nucleic Acids the largest line at 58.07% of 2025 revenue and Exosomes/Microvesicles the fastest-growing at 17.7%. The full report breaks North America out along every axis and by country.
United States
Sets the pace for North America at 90.2% of it, growing 3.3×.
- In region 1 of 2
- Of region 90.2%
- Of global 37.9%
- Revenue $2.75B → $8.98B
The largest single market in North America is the United States, at USD 2.75 billion in 2025 and USD 8.98 billion in 2034. Carrying 90.16% of the region in the base year, it sets North America's direction instead of merely contributing to it. Against regional totals of USD 3.05 billion in 2025 and USD 9.98 billion in 2034, it is the country the full report breaks out in detail.
Demand in the United States follows the biomarker mix reported at global level: Circulating Nucleic Acids is the largest line at 58.07% of 2025 revenue, moving to 62.02% by 2034, while Exosomes/Microvesicles grows fastest at 17.7% and takes its share from 12% to 15.01%. Its 90.16% weight in North America means those movements carry straight into the regional totals. Revenue by biomarker for the United States is reported separately in the full report.
In the United States, liquid biopsy assays fall under the Food and Drug Administration's oversight of in vitro diagnostics. A test marketed as a commercial kit generally needs FDA premarketing review, most often through the de novo or premarket approval route, particularly when the assay is positioned as a companion diagnostic tied to a specific therapy's label. Tests instead developed and run within a single certified laboratory can proceed as laboratory-developed tests under the Clinical Laboratory Improvement Amendments framework, overseen by the Centers for Medicare and Medicaid Services, though the FDA has moved to bring more of these under its own review. Either path requires validated analytical performance and clear labelling of the test's intended use.
The suppliers tracked in this study (QIAGEN, Myriad Genetics, Inc., BIOCEPT, Inc., Guardant Health, Inc., F. Hoffmann-La Roche Ltd., Illumina, Inc., Angle plc, Oncimmune, Thermo Fisher Scientific, Inc., Lucence health Inc., FreenomeHoldings, Inc. and EPIGENOMICS AG) compete in the United States across the biomarker lines above. Two different problems sit on the same axis: holding Circulating Nucleic Acids at 58.07% of 2025 revenue, and taking Exosomes/Microvesicles while it grows at 17.7%. Per-company positioning and share at country level are in the full report only.
Canada
2nd-largest in North America, growing 3.3×.
- In region 2 of 2
- Of region 9.8%
- Of global 4.1%
- Revenue $0.30B → $1B
Within North America, Canada accounts for 9.84% of regional revenue and 4.14% of the global total, worth USD 0.3 billion in 2025 and USD 1 billion by 2034.
Europe Market Analysis
The 2nd-largest region covered — 2 points of share move elsewhere by 2034, while revenue still grows 3.3×.
- Rank 2 of 5
- 2025 share 27%
- By 2034 25%
- Revenue $1.96B → $6.56B
27.03% of the global liquid biopsy market sits in Europe in 2025, worth USD 1.96 billion rising to USD 6.56 billion in 2034. It is a leading region on this axis, second by revenue throughout the period.
By 2034 the share stands at 25%, though revenue still rises throughout; the shift is in the region's weight against faster-growing ones, which is not the same as weakening demand.
Segment composition follows the global pattern: Circulating Nucleic Acids largest at 58.07% of 2025 revenue, Exosomes/Microvesicles fastest at 17.7%. Revenue for Europe is broken out by every segmentation axis and by country in the full report.
Germany
The largest market in Europe, growing 3.3×.
- In region 1 of 2
- Of region 30.1%
- Of global 8.1%
- Revenue $0.59B → $1.97B
30.1% of Europe's base-year revenue comes from Germany; USD 0.59 billion, rising to USD 1.97 billion by 2034. It accounts for 30.1% of regional revenue in the base year, the largest single share without dominating the region outright. Set against USD 1.96 billion and USD 6.56 billion for the region, it is why this market, and not a smaller one, is the one reported in full.
The biomarker pattern in Germany is the global one: 58.07% of 2025 revenue in Circulating Nucleic Acids, 62.02% by 2034, against 17.7% growth in Exosomes/Microvesicles taking it from 12% to 15.01%. Its 30.1% weight in Europe means those movements carry straight into the regional totals. Germany carries its own biomarker breakdown in the full report.
In Germany, liquid biopsy tests are governed by the European Union's In Vitro Diagnostic Regulation, implemented alongside national medical device law. Most oncology-focused liquid biopsy assays are classified as higher-risk in vitro diagnostics, requiring assessment by an independent notified body before a manufacturer may apply the CE mark and place the test on the market. The regulation obliges the manufacturer to demonstrate analytical and clinical validity, maintain a quality management system, and keep post-market surveillance records that feed into vigilance reporting overseen by the national competent authority, the Federal Institute for Drugs and Medical Devices. Labelling must state the assay's intended purpose and performance characteristics in the requisite languages.
QIAGEN, Myriad Genetics, Inc., BIOCEPT, Inc., Guardant Health, Inc., F. Hoffmann-La Roche Ltd., Illumina, Inc., Angle plc, Oncimmune, Thermo Fisher Scientific, Inc., Lucence health Inc., FreenomeHoldings, Inc. and EPIGENOMICS AG are the suppliers covered in Germany. Volume sits in Circulating Nucleic Acids at 58.07% of 2025 revenue; movement sits in Exosomes/Microvesicles at 17.7% growth. The commercial size of that position is USD 1.96 billion in 2025 and USD 6.56 billion by 2034, 27.03% of the global total in the base year.
United Kingdom
2nd-largest in Europe, growing 3.3×.
- In region 2 of 2
- Of region 25%
- Of global 6.8%
- Revenue $0.49B → $1.64B
6.76% of global revenue is generated in the United Kingdom; USD 0.49 billion in 2025, reaching USD 1.64 billion in 2034, and 25% of Europe.
Asia Pacific Market Analysis
The 3rd-largest region covered, and the one gaining the most — it picks up 4.9 points of share by 2034, while revenue still grows 4.4×.
- Rank 3 of 5
- 2025 share 22.1%
- By 2034 27%
- Revenue $1.60B → $7.09B
22.07% of the global liquid biopsy market sits in Asia Pacific in 2025, worth USD 1.6 billion on the way to USD 7.09 billion by 2034. That makes it the third-largest region covered, in 2025 and again in 2034.
Its share rises to 27.01% over the forecast period, on growth above the market's own 14.89%, and with a bigger contribution to the revenue added over the period than the base-year figure suggests.
Within the region the biomarker split tracks the global one; 58.07% of 2025 revenue in Circulating Nucleic Acids, fastest growth of 17.7% in Exosomes/Microvesicles. Revenue for Asia Pacific is broken out by every segmentation axis and by country in the full report.
China
The largest market in Asia Pacific, growing 4.4×.
- In region 1 of 3
- Of region 35%
- Of global 7.7%
- Revenue $0.56B → $2.48B
USD 0.56 billion of Asia Pacific's 2025 revenue is generated in China, the region's largest market, reaching USD 2.48 billion by 2034. Its 35% of base-year regional revenue leads the region, though enough sits elsewhere that Asia Pacific is not a proxy for it. Regional revenue of USD 1.6 billion in 2025 and USD 7.09 billion in 2034 sits around it, and it is the country used wherever the full report cuts a figure by geography.
The biomarker pattern in China is the global one: 58.07% of 2025 revenue in Circulating Nucleic Acids, 62.02% by 2034, against 17.7% growth in Exosomes/Microvesicles taking it from 12% to 15.01%. With 35% of Asia Pacific concentrated here, a change in this country's mix is visible in the regional figures instead of being diluted by its neighbours. Per-biomarker revenue for China appears on its own in the full report.
In China, liquid biopsy products are regulated as in vitro diagnostic reagents by the National Medical Products Administration. Because these assays are typically used to detect or profile cancer, they fall into the highest domestic risk category, which calls for clinical trial data generated within the country and a full registration dossier before the product may be sold. Approval authority rests with the national regulator itself, not with provincial bodies, and once granted, a manufacturer must maintain a domestic quality system, renew its registration periodically, and ensure labelling and instructions for use are presented in Chinese and aligned with the approved indication. Companion-diagnostic claims tied to a specific drug draw additional scrutiny from the review centre.
QIAGEN, Myriad Genetics, Inc., BIOCEPT, Inc., Guardant Health, Inc., F. Hoffmann-La Roche Ltd., Illumina, Inc., Angle plc, Oncimmune, Thermo Fisher Scientific, Inc., Lucence health Inc., FreenomeHoldings, Inc. and EPIGENOMICS AG are the suppliers covered in China. Two different problems sit on the same axis: holding Circulating Nucleic Acids at 58.07% of 2025 revenue, and taking Exosomes/Microvesicles while it grows at 17.7%. A supplier weighted toward Asia Pacific is competing over a base of USD 1.6 billion in 2025 reaching USD 7.09 billion by 2034, 22.07% of global revenue at the start of that period.
Japan
2nd-largest in Asia Pacific, growing 4.4×.
- In region 2 of 3
- Of region 28.1%
- Of global 6.2%
- Revenue $0.45B → $1.99B
Within Asia Pacific, Japan accounts for 28.13% of regional revenue and 6.21% of the global total, worth USD 0.45 billion in 2025 and USD 1.99 billion by 2034.
India
3rd-largest in Asia Pacific, growing 4.5×.
- In region 3 of 3
- Of region 11.9%
- Of global 2.6%
- Revenue $0.19B → $0.85B
Within Asia Pacific, India accounts for 11.88% of regional revenue and 2.62% of the global total, worth USD 0.19 billion in 2025 and USD 0.85 billion by 2034.
Latin America Market Analysis
The 4th-largest region covered — it picks up 0.5 points of share by 2034, while revenue still grows 4.0×.
- Rank 4 of 5
- 2025 share 5%
- By 2034 5.5%
- Revenue $0.36B → $1.44B
Latin America holds 4.97% of the global liquid biopsy market in 2025, worth USD 0.36 billion rising to USD 1.44 billion in 2034. Among the five regions it ranks fourth by revenue in both years.
Share climbs to 5.49% by 2034, at a pace above the 14.89% global rate, so this region warrants separate treatment and should not be scaled off the total.
Within the region the biomarker split tracks the global one; 58.07% of 2025 revenue in Circulating Nucleic Acids, fastest growth of 17.7% in Exosomes/Microvesicles. Per-axis and per-country detail for Latin America sits in the full report.
Brazil
The largest market in Latin America, growing 4.1×.
- In region 1 of 2
- Of region 44.4%
- Of global 2.2%
- Revenue $0.16B → $0.65B
The largest single market in Latin America is Brazil, at USD 0.16 billion in 2025 and USD 0.65 billion in 2034. Its 44.44% of base-year regional revenue leads the region, though enough sits elsewhere that Latin America is not a proxy for it. Set against USD 0.36 billion and USD 1.44 billion for the region, it is why this market, and not a smaller one, is the one reported in full.
Demand in Brazil follows the biomarker mix reported at global level: Circulating Nucleic Acids is the largest line at 58.07% of 2025 revenue, moving to 62.02% by 2034, while Exosomes/Microvesicles grows fastest at 17.7% and takes its share from 12% to 15.01%. Its 44.44% weight in Latin America means those movements carry straight into the regional totals. Per-biomarker revenue for Brazil appears on its own in the full report.
In Brazil, liquid biopsy tests are regulated as in vitro diagnostic products by Anvisa, the national health surveillance agency. A supplier must register the assay before marketing it, with the depth of review tied to the risk class the product is assigned; oncology assays used to guide treatment decisions typically sit in a higher class and face closer scrutiny of analytical and clinical performance data. Manufacturing sites are expected to hold good manufacturing practice certification recognised by Anvisa, and the product's labelling and instructions for use must be presented in Portuguese and conform to the agency's technical requirements for diagnostic kits. Post-market changes to the assay generally require a fresh notification or amendment to the existing registration.
Competition in Brazil runs between the suppliers this study tracks: QIAGEN, Myriad Genetics, Inc., BIOCEPT, Inc., Guardant Health, Inc., F. Hoffmann-La Roche Ltd., Illumina, Inc., Angle plc, Oncimmune, Thermo Fisher Scientific, Inc., Lucence health Inc., FreenomeHoldings, Inc. and EPIGENOMICS AG. Volume sits in Circulating Nucleic Acids at 58.07% of 2025 revenue; movement sits in Exosomes/Microvesicles at 17.7% growth. That makes Latin America a 4.97% share of 2025 global revenue, USD 0.36 billion rising to USD 1.44 billion, for any supplier deciding where to concentrate.
Mexico
2nd-largest in Latin America, growing 3.9×.
- In region 2 of 2
- Of region 30.6%
- Of global 1.5%
- Revenue $0.11B → $0.43B
1.52% of global revenue is generated in Mexico; USD 0.11 billion in 2025, reaching USD 0.43 billion in 2034, and 30.56% of Latin America.
Middle East and Africa Market Analysis
The 5th-largest region covered — it picks up 0.6 points of share by 2034, while revenue still grows 4.2×.
- Rank 5 of 5
- 2025 share 3.9%
- By 2034 4.5%
- Revenue $0.28B → $1.18B
3.86% of the global liquid biopsy market sits in Middle East and Africa in 2025, worth USD 0.28 billion rising to USD 1.18 billion in 2034. It is a marginal region on this axis, fifth by revenue throughout the period.
Share climbs to 4.5% by 2034, on growth above the market's own 14.89%, and with a bigger contribution to the revenue added over the period than the base-year figure suggests.
The biomarker mix reported at global level applies here, with Circulating Nucleic Acids the largest line at 58.07% of 2025 revenue and Exosomes/Microvesicles the fastest-growing at 17.7%. Revenue for Middle East and Africa is broken out by every segmentation axis and by country in the full report.
Saudi Arabia
The largest market in Middle East and Africa, growing 4.1×.
- In region 1 of 2
- Of region 35.7%
- Of global 1.4%
- Revenue $0.10B → $0.41B
USD 0.1 billion of Middle East and Africa's 2025 revenue is generated in Saudi Arabia, the region's largest market, reaching USD 0.41 billion by 2034. Its 35.71% of base-year regional revenue leads the region, though enough sits elsewhere that Middle East and Africa is not a proxy for it. Set against USD 0.28 billion and USD 1.18 billion for the region, it is why this market, and not a smaller one, is the one reported in full.
Saudi Arabia buys along the same lines as the market globally; Circulating Nucleic Acids first at 58.07% of 2025 revenue and 62.02% in 2034, Exosomes/Microvesicles fastest at 17.7% on a share moving from 12% to 15.01%. Because the country carries 35.71% of Middle East and Africa, a movement in its own mix shows up in the regional totals instead of being averaged away by neighbouring markets. Per-biomarker revenue for Saudi Arabia appears on its own in the full report.
In Saudi Arabia, liquid biopsy tests are regulated as in vitro diagnostic medical devices by the Saudi Food and Drug Authority. A supplier registers the product through the authority's medical device marketing authorisation system, and the review often relies on prior clearance from a recognised reference regulator such as the US or European framework, supplemented by local technical review. Devices must be listed by an authorised local representative established in the Kingdom, and labelling must appear in Arabic alongside the original language, stating intended use and handling requirements. Classification follows the same risk-based logic applied elsewhere in the Gulf region, with higher-risk oncology assays subject to more detailed dossier review before market entry is granted.
QIAGEN, Myriad Genetics, Inc., BIOCEPT, Inc., Guardant Health, Inc., F. Hoffmann-La Roche Ltd., Illumina, Inc., Angle plc, Oncimmune, Thermo Fisher Scientific, Inc., Lucence health Inc., FreenomeHoldings, Inc. and EPIGENOMICS AG are the suppliers covered in Saudi Arabia. Two different problems sit on the same axis: holding Circulating Nucleic Acids at 58.07% of 2025 revenue, and taking Exosomes/Microvesicles while it grows at 17.7%. A supplier weighted toward Middle East and Africa is competing over a base of USD 0.28 billion in 2025 reaching USD 1.18 billion by 2034, 3.86% of global revenue at the start of that period.
South Africa
2nd-largest in Middle East and Africa, growing 4.3×.
- In region 2 of 2
- Of region 25%
- Of global 1%
- Revenue $0.07B → $0.30B
Within Middle East and Africa, South Africa accounts for 25% of regional revenue and 0.97% of the global total, worth USD 0.07 billion in 2025 and USD 0.3 billion by 2034.
Request this sample to see the full data tables and segment-level detail behind this analysis.
Report Coverage
This report assesses the market across every segment, with revenue and a growth rate for each line in each year of the study period. It covers the drivers, trends, opportunities, restraints and challenges shaping growth, the competitive landscape and the companies profiled, and the research methodology behind every estimate. Segmentation is reported by biomarker, technology, application, end user, sample type, and regional analysis covers North America, Europe, Asia Pacific, Latin America, Middle East and Africa, each broken out by country.
Competitive Landscape
Position on the Biomarker Axis Decides Competitive Standing
Twelve suppliers are covered: QIAGEN, Myriad Genetics, Inc., BIOCEPT, Inc., Guardant Health, Inc., F. Hoffmann-La Roche Ltd., Illumina, Inc., Angle plc, Oncimmune, Thermo Fisher Scientific, Inc., Lucence health Inc., FreenomeHoldings, Inc. and EPIGENOMICS AG.
Where suppliers actually compete is along the biomarker axis. The largest block of revenue is Circulating Nucleic Acids: USD 4.21 billion in 2025 at 58.07% of the total, 62.02% in 2034. Incumbency there is expensive to challenge. Share moves in Exosomes/Microvesicles, growing 17.7% against 10.8% for CTC. The two rarely sit with the same supplier, and that is the reason a USD 7.25 billion market is not already consolidated.
What separates suppliers in this market is regulatory depth rather than manufacturing scale: an assay tied to an approved companion-diagnostic label carries years of paired clinical-trial evidence that a newer entrant cannot quickly replicate. Established players hold an edge in laboratory throughput, payer-contracting relationships, and the breadth of cancer types their panels cover, while smaller and regional entrants compete on turnaround time, price for research-use-only testing, and focus on a single indication or biomarker class where a large panel is unnecessary. Distribution matters less through resellers than through direct relationships with oncology networks and pharmaceutical sponsors running biomarker-driven trials.
Presence matters unevenly by region. With 42.07% of 2025 revenue in North America and 27.03% in Europe, a supplier's coverage of those two decides most of its addressable base before any product question arises.
Per-company profiles, financials, share and development history are in the full report and not here.
List of Key Liquid Biopsy Market Companies Profiled
12 companies profiled. Company profiles, including financials, product portfolios and recent developments, are part of the full report.
- QIAGEN(Germany)
- Myriad Genetics, Inc.(United States)
- BIOCEPT, Inc.(United States)
- Guardant Health, Inc.(United States)
- F. Hoffmann-La Roche Ltd.(Switzerland)
- Illumina, Inc.(United States)
- Angle plc(United Kingdom)
- Oncimmune(United Kingdom)
- Thermo Fisher Scientific, Inc.(United States)
- Lucence health Inc.
- FreenomeHoldings, Inc.
- EPIGENOMICS AG(Germany)
Geographic Coverage
Every market below is broken out separately in the report.
North America
3Europe
8Asia Pacific
12Latin America
3Middle East and Africa
4Key Insights
Report Scope
Study parameters & segmentationThis study covers market size and forecasts over the 2020–2034 period, segmentation across 5 axes (Biomarker, Technology, Application, End User, Sample Type), regional analysis for 5 regions and their constituent countries, a competitive landscape profiling 12 key companies, and the research methodology behind every estimate.
Segmentation
5 axes + regionFull chapter-and-section structure of the report. Segment, region, and company breakdowns are listed as scope. The underlying figures are in the sample and full report.
Table of Contents+−
Chapter 1.Executive Summary
Chapter 2.Premium Insights
Chapter 3.Market Definition
Chapter 4.Research Methodology
Chapter 5.Strategic Imperatives & Market Outlook
Chapter 6.Go-to-Market (GTM) Strategies
Chapter 7.Market Trends, Strategy & Dynamics
Chapter 8.Porter's Five Forces
Chapter 9.PESTEL Analysis
Chapter 10.Value Chain Analysis
Chapter 11.Supply Chain Analysis
Chapter 12.Macro-Economic Factors
Chapter 13.Market Cost Analysis
Chapter 14.Market Supply-Side Analysis
Chapter 15.Global Liquid Biopsy Market Size & Projections, 2020–2034, Revenue (USD Billion)
Chapter 16.Global Liquid Biopsy Market Overview, By Biomarker, 2020–2034, Revenue (USD Billion)
Chapter 17.Global Liquid Biopsy Market Overview, By Technology, 2020–2034, Revenue (USD Billion)
Chapter 18.Global Liquid Biopsy Market Overview, By Application, 2020–2034, Revenue (USD Billion)
Chapter 19.Global Liquid Biopsy Market Overview, By End User, 2020–2034, Revenue (USD Billion)
Chapter 20.Global Liquid Biopsy Market Overview, By Sample Type, 2020–2034, Revenue (USD Billion)
Chapter 21.Global Liquid Biopsy Market Size — Segment Comparison
Chapter 22.Global Liquid Biopsy Geography Overview, 2020–2034, Revenue (USD Billion)
Chapter 23.North America Liquid Biopsy Market Deep-Dive, 2020–2034, Revenue (USD Billion)
Chapter 24.Europe Liquid Biopsy Market Deep-Dive, 2020–2034, Revenue (USD Billion)
Chapter 25.Asia Pacific Liquid Biopsy Market Deep-Dive, 2020–2034, Revenue (USD Billion)
Chapter 26.Latin America Liquid Biopsy Market Deep-Dive, 2020–2034, Revenue (USD Billion)
Chapter 27.Middle East and Africa Liquid Biopsy Market Deep-Dive, 2020–2034, Revenue (USD Billion)
Chapter 28.Application / Use-Case Analysis
Chapter 29.Vendor Capability Scorecard
Chapter 30.Scenario Forecasts
Chapter 31.Top 10 Key Clients of Top 10 Players
Chapter 32.Top 10 Suppliers
Chapter 33.Competitive Landscape
Chapter 34.Partnerships & M&A
Chapter 35.Key Vendor Analysis
Chapter 36.Marketing Strategy Analysis, Distributors & Traders
Chapter 37.Outlook of the Market
Chapter 38.Concluding Analyst Note
List of Figures+−
Structural index generated from this report's own section headings, not verified against the delivered report's actual figure numbering.
List of Tables+−
Structural index generated from this report's own section headings, not verified against the delivered report's actual table numbering.
Segmentation Analysis
5 axesBy Biomarker
4- 01Circulating Nucleic Acids
- 02CTC
- 03Exosomes/Microvesicles
- 04Circulating Proteins
By Technology
2- 01Multi-gene-parallel Analysis (NGS)
- 02Single Gene Analysis (PCR Microarrays)
By Application
4- 01Diagnosis & Companion Diagnostics
- 02Treatment Selection & Monitoring
- 03Recurrence/MRD Monitoring
- 04Early Cancer Screening
By End User
4- 01Reference/Central Laboratories
- 02Hospitals & Diagnostic Laboratories
- 03Pharmaceutical & Biotechnology Companies
- 04Academic & Research Institutes
By Sample Type
3- 01Blood-based (Plasma/Serum)
- 02Urine-based
- 03Other Biofluids (CSF, Pleural Fluid, Saliva)
Segment categories shown for scope reference. See the Summary tab for revenue share by By Biomarker. Full segment-by-segment detail across every axis is available in the sample and full report.
Research approach
A market size is a claim about the world, and a claim is only as good as the route to it. Every study is built upward from units and prices — what is actually produced, sold or performed, at what it actually changes hands for — rather than from a headline figure divided downwards. Disclosed company revenue is then used to check that build, not to produce it.
The estimate is built upward from the number of liquid biopsy tests run each year across companion-diagnostic, treatment-monitoring, recurrence and screening use, multiplied by the realized price per test in each channel, since price differs sharply between a reimbursed companion-diagnostic panel and a research-use assay. Test volumes are anchored to disclosed sample throughput and testing-center capacity for the largest commercial laboratories. That bottom-up build is then checked against the disclosed oncology testing revenue reported by the public suppliers named in this report. Where the two disagreed, for example on urine and other biofluid volumes with thinner public disclosure, the bottom-up test-count assumption was the figure corrected, not the revenue check.
The four stages
The same sequence runs behind every published study, whatever the industry. The order matters as much as the steps: the segment axes are fixed before any number is collected, so the model is never reshaped to fit whatever data happens to turn up.
What the build rests on, and what checks it
The two are not interchangeable. The left column produces the number; the right column tests it. When the check disagrees with the build, the answer is to find which bottom-up assumption is wrong — a unit count, a price, a take-up rate — not to split the difference between them.
- Volume actually transacted — units produced, installed, dispensed or procedures performed, counted at the level each is genuinely recorded
- Realised pricing by tier and channel, rather than one blended average applied across the whole market
- Take-up and frequency: how much of the addressable base buys, and how often it repeats
- Disclosed revenue of the companies serving the market, where filings separate it far enough to be usable
- Buyer-side spending totals — capital budgets, procurement lines, or the output of the end market the product is bought against
- Trade and customs flows, where the product crosses borders in a separately recorded form
Data sources
Published data establishes what happened. Only the people transacting in a market can say why, and what is about to change — so the two are collected separately and weighted differently.
- Commercial and product leadership at the companies that supply the market
- Procurement and specification leads at the organisations that buy it
- Distributors, integrators and channel partners, where the market is served indirectly
- Regulatory and standards specialists, where approval governs what can be sold at all
- Company filings, annual reports and investor disclosure
- Government statistics, customs records and regulatory registers
- Trade association output and standards-body publications
- Technical and peer-reviewed literature, where the market rests on a clinical or engineering claim
Primary interviews target laboratory directors and molecular pathology heads who set which liquid biopsy panels a hospital or reference lab adopts, procurement and managed-care contracting staff who negotiate payer coverage, and regulatory affairs leads at diagnostic manufacturers who track companion-diagnostic clearance timelines. Clinical trial operations staff at pharmaceutical sponsors are also sampled, since their patient-stratification and monitoring protocols drive a growing share of test volume outside routine clinical care. Sampling weights toward the United States and Western Europe, where companion-diagnostic reimbursement is most established, with a smaller but deliberate sample in China and Japan to capture the fastest-adopting Asia Pacific testing centers.
Desk research draws on the FDA's companion-diagnostic device approval and premarket-approval listings, which record which liquid biopsy assays are cleared for which drug label; the CPT and HCPCS molecular pathology billing codes and the MolDx local coverage determinations that set Medicare reimbursement for specific assays; and clinicaltrials.gov records of trials that specify a named liquid biopsy test as a stratification or monitoring biomarker. European in-vitro diagnostic registration filings under the IVDR supplement the US-centric approval data. Peer-reviewed assay validation studies, read for reported sensitivity and sample-volume requirements, fill in technical detail the regulatory filings do not disclose.
Desk research runs across proprietary research databases including Factiva, OneSource and Hoovers alongside the public sources above. Modelling and statistical validation are run in SAS and SPSS.
Forecasting
The forecast is not a growth rate applied to a base year. It is built from the drivers that are expected to change, each one stated so a reader can disagree with it.
The forecast carries forward the shift from single-biomarker assays toward multi-gene panels, and from late-stage treatment selection toward earlier recurrence monitoring and screening, at the pace those uses have cleared regulatory and reimbursement hurdles historically. Panel pricing is assumed to keep falling as sequencing throughput improves, and that decline is treated as the main lever widening addressable test volume, not any single new approval. The period immediately after 2020 is normalized for the disruption to routine cancer screening and elective diagnostic visits, so that dip is not read as a change in underlying demand. The forecast holds only if reimbursement for recurrence and screening indications continues to broaden at roughly its recent pace.
Triangulation and validation
No figure enters a report on the strength of one source. Where the two sizing routes disagree the difference is not averaged away — the assumption causing it is isolated, tested against a third independent measure, and either corrected or carried forward as a stated limitation. Historical years are back-tested against the growth actually recorded before any forecast is allowed to run forward from them.
Historical figures are back-tested against recorded year-on-year growth in the largest disclosed oncology testing businesses to confirm the built-up volumes do not imply faster growth than those companies actually reported. Segment share shifts, particularly the move toward multi-gene panels and away from single-gene assays, were reviewed against the same laboratory-director interviews used for primary research instead of being accepted from the volume model alone. Sensitivities were run on reimbursement timing for screening and recurrence indications and on panel-price decline, since those two assumptions move the forecast further than any single driver. A slower reimbursement path than assumed here would compress the later forecast years without changing the early-year figures.
Confidence and limitations
Where an estimate is firm and where it is not is stated rather than left to be inferred from the precision of the number.
Confidence is firmest in the companion-diagnostic and treatment-monitoring segments, where disclosed assay volumes and payer coverage decisions are directly observable. It is thinner in early cancer screening and in urine and other biofluid testing, where commercial volume is still small and less consistently disclosed. A material change in payer coverage for multi-cancer screening, or a large diagnostic manufacturer disclosing volumes well outside the range assumed here, would be grounds to revise the estimate. This market is sized as medium confidence: triangulated from proxy volumes and adjacent disclosures rather than anchored directly to every named company's own reported liquid biopsy revenue.
Every report purchase includes direct access to the lead analyst for scoping questions on the data, at no extra cost and with no separate booking process.
Request a tailored breakdown by geography, segment, or competitor set beyond what's in the standard report.
Questions This Report Answers
6 questionsWhat is the market size and growth rate, globally and by region?
How is the market segmented, and which segments lead?
Which regions and countries are covered, and how do they compare?
What are the key drivers, restraints, opportunities and challenges?
Who are the leading companies operating in this market?
What trends are expected to shape the market through the forecast period?
Frequently Asked Questions
01What is the Liquid Biopsy Market projected to reach?
USD 26.25 Billion by 2034, CAGR 14.89%
02What years does this report cover?
Study period 2020–2034, base year 2025, historical data 2020-2024, forecast period 2026-2034.
03Which regions are covered?
North America, Europe, Asia Pacific, Latin America, Middle East and Africa.
04Which region accounted for the largest market share?
North America leads with 42.07% of global revenue through 2034.
05Which segment leads the market?
Circulating Nucleic Acids is the largest line by biomarker, at 58.07% of revenue in 2025.
06Who are the key companies profiled?
QIAGEN, Myriad Genetics, Inc., BIOCEPT, Inc., Guardant Health, Inc., F. Hoffmann-La Roche Ltd., Illumina, Inc., Angle plc, Oncimmune, Thermo Fisher Scientific, Inc., Lucence health Inc., FreenomeHoldings, Inc., EPIGENOMICS AG. Full profiles are part of the paid report.
07Can the segmentation be customized?
Yes. Custom data cuts by geography, segment, or competitor set are available on request.
Why choose CDI
Need this report shaped around your question?
The scope isn't fixed. Tell us what your team needs that the standard edition doesn't cover, and an analyst will come back on what can be adjusted and how long it takes, before you commit to anything.
Most licences include 30–60 hours of customization at no extra cost. See what each licence includes
Additional Companies
Add competitors, suppliers or the peer set you benchmark against to the companies already covered.
Deeper Competitive View
Sharpen the landscape work around your own position: product line, channel, or a named shortlist of rivals.
Extra Segment Splits
Break the market down along an axis the standard scope doesn't cut it by, or go a level deeper inside one.
Application Focus
Narrow the analysis to the specific use cases and end users your team actually sells into.
Different Time Frame
Move the base year, or widen the historical and forecast windows the study is built on.
Country-Level Detail
Go below region level into the individual countries that matter to you, rather than the standard geography split.